Additional Metadata
Keywords advanced cancer, analgesia, article, atrasentan, bevacizumab, calcitriol, cancer chemotherapy, cancer combination chemotherapy, cardiovascular disease, castration resistant prostate cancer, clinical assessment, clinical trial, clodronic acid, diarrhea, docetaxel, drug dose escalation, drug efficacy, drug megadose, drug withdrawal, estramustine, fatigue, febrile neutropenia, fever, gastrointestinal toxicity, granulocyte macrophage colony stimulating factor vaccine, heart disease, human, hydrocortisone, infection, low drug dose, lung embolism, mitoxantrone, multiple cycle treatment, musculoskeletal disease, n (3 methoxy 5 methyl 2 pyrazinyl) 2 [4 (1,3,4 oxadiazol 2 yl)phenyl] 3 pyridinesulfonamide, nail disease, nausea and vomiting, neutropenia, outcome assessment, palliative therapy, pamidronic acid, predictor variable, prednisone, priority journal, prognosis, prostate cancer, prostate specific antigen, risedronic acid, risk factor, satraplatin, sensory neuropathy, steroid 17,20 lyase, steroid 17alpha monooxygenase, thrombosis, treatment duration, treatment response, zoledronic acid
Persistent URL dx.doi.org/10.1016/S0959-8049(09)70029-2, hdl.handle.net/1765/17579
Citation
Meulenbeld, H.J., Hamberg, A.P., & de Wit, R.. (2009). Chemotherapy in patients with castration-resistant prostate cancer. European Journal of Cancer, 45(SUPPL. 1), 161–171. doi:10.1016/S0959-8049(09)70029-2